



Clinical trial results:

A multicenter, single-arm trial evaluating the safety and efficacy of DEB025/Alisporivir in combination with pegylated interferon-2a and ribavirin (peg-IFN2a/RBV) in protease inhibitor treatment failure patients with chronic hepatitis C genotype 1

Summary

EudraCT number	2011-004653-31
Trial protocol	DE ES GB IT
Global end of trial date	29 May 2012

Results information

Result version number	v1 (current)
This version publication date	16 October 2016
First version publication date	16 October 2016

Trial information

Trial identification

Sponsor protocol code	CDEB025A2306
-----------------------	--------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01500772
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Novartis Pharma AG
Sponsor organisation address	CH-4002, Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis Pharma AG, +41 613241111 ,
Scientific contact	Clinical Disclosure Office, Novartis Pharma AG, +41 613241111 ,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	29 May 2012
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	29 May 2012
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

The primary objective is to evaluate the efficacy (SVR12 LOQ) of triple combination therapy of DEB025 400 mg BID and standard dose pegIFN/RBV for 48 weeks in chronic hepatitis C GT 1 patients who failed prior treatment with PI.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 March 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 6
Worldwide total number of subjects	6
EEA total number of subjects	6

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	6
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

The duration of screening was of 1 to 42 days, with a possibility to be extended for another 42 days. However, all patients completed screening within the first 42 days period.

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Arm title	DEB 400 mg BID + PEG + RBV
------------------	----------------------------

Arm description: -

Arm type	Experimental
Investigational medicinal product name	DEB025
Investigational medicinal product code	
Other name	lisporivir
Pharmaceutical forms	Capsule, soft
Routes of administration	Oral use

Dosage and administration details:

2 capsules (400 mg) BID for 48 weeks

Investigational medicinal product name	PegIFN
Investigational medicinal product code	
Other name	Pegasys®
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

180 µg subcutaneous injection (s.c.) once weekly for 48 weeks

Investigational medicinal product name	Ribavirin
Investigational medicinal product code	
Other name	Copegus®
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

1000 mg/day (<75 kg) or 1200 mg/day (≥75 kg) orally in two divided doses for 48 weeks

Number of subjects in period 1	DEB 400 mg BID + PEG + RBV
Started	6
Completed	0
Not completed	6
Early termination of the study	6

Baseline characteristics

Reporting groups

Reporting group title	Overall trial
-----------------------	---------------

Reporting group description: -

Reporting group values	Overall trial	Total	
Number of subjects	6	6	
Age categorical Units: Subjects			
Adults (18-64 years)	6	6	
Gender categorical Units: Subjects			
Female	3	3	
Male	3	3	

End points

End points reporting groups

Reporting group title	DEB 400 mg BID + PEG + RBV
-----------------------	----------------------------

Reporting group description: -

Primary: SVR12

End point title	SVR12 ^[1]
-----------------	----------------------

End point description:

SVR12 is defined as HCV RNA laboratory value <LOQ, (Level of quantification) 12 weeks after the end of treatment. The assay used in this study has a reported LOQ of 25 IU/ml.

End point type	Primary
----------------	---------

End point timeframe:

12 weeks after the end of treatment

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to early termination of the study, none of the planned study objectives could be evaluated.

End point values	DEB 400 mg BID + PEG + RBV			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[2]			
Units: percentage of participants				
number (not applicable)				

Notes:

[2] - Due to early termination of the study, none of the planned study objectives could be evaluated.

Statistical analyses

No statistical analyses for this end point

Secondary: SVR24

End point title	SVR24
-----------------	-------

End point description:

SVR24 is defined as HCV RNA laboratory value <LOQ, (Level of quantification) 24 weeks after the end of treatment. The assay used in this study has a reported LOQ of 25 IU/ml

End point type	Secondary
----------------	-----------

End point timeframe:

24 weeks after the end of treatment

End point values	DEB 400 mg BID + PEG + RBV			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[3]			
Units: percentage of participants				
number (not applicable)				

Notes:

[3] - Due to early termination of the study, none of the planned study objectives could be evaluated.

Statistical analyses

No statistical analyses for this end point

Secondary: SVR12LOD

End point title	SVR12LOD
End point description:	SVR12LOD is defined as HCV RNA laboratory value <LOD, 12 weeks after the end of treatment. The assay used in this study as a reported LOD of 10 IU/ml.
End point type	Secondary
End point timeframe:	12 weeks after the end of treatment

End point values	DEB 400 mg BID + PEG + RBV			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[4]			
Units: percentage of participants				
number (not applicable)				

Notes:

[4] - Due to early termination of the study, none of the planned study objectives could be evaluated.

Statistical analyses

No statistical analyses for this end point

Secondary: Overall safety profile

End point title	Overall safety profile
End point description:	The evaluation the overall safety profile will be measured by proportion of patients that discontinue study drug or require dose reduction or dose interruption due to treatment-emergent AEs.
End point type	Secondary
End point timeframe:	48 weeks

End point values	DEB 400 mg BID + PEG + RBV			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[5]			
Units: percentage of participants				
number (not applicable)				

Notes:

[5] - Due to early termination of the study, none of the planned study objectives could be evaluated.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Serious Adverse Events are monitored from date of First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All other adverse events are monitored from First Patient First Treatment until Last Patient Last Visit .

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	15.0

Reporting groups

Reporting group title	DEB 400mg BID+PEG+RBV
-----------------------	-----------------------

Reporting group description:

DEB 400mg BID+PEG+RBV

Serious adverse events	DEB 400mg BID+PEG+RBV		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 6 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	DEB 400mg BID+PEG+RBV		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5 / 6 (83.33%)		
Vascular disorders			
HYPERTENSION			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Nervous system disorders			
HEADACHE			
subjects affected / exposed	4 / 6 (66.67%)		
occurrences (all)	4		
Blood and lymphatic system disorders			
NEUTROPENIA			

<p>subjects affected / exposed occurrences (all)</p> <p>THROMBOCYTOPENIA subjects affected / exposed occurrences (all)</p>	<p>1 / 6 (16.67%) 1</p> <p>2 / 6 (33.33%) 2</p>		
<p>General disorders and administration site conditions</p> <p>ASTHENIA subjects affected / exposed occurrences (all)</p> <p>CHILLS subjects affected / exposed occurrences (all)</p> <p>FATIGUE subjects affected / exposed occurrences (all)</p> <p>PYREXIA subjects affected / exposed occurrences (all)</p>	<p>1 / 6 (16.67%) 1</p> <p>1 / 6 (16.67%) 1</p> <p>1 / 6 (16.67%) 1</p> <p>2 / 6 (33.33%) 2</p>		
<p>Gastrointestinal disorders</p> <p>NAUSEA subjects affected / exposed occurrences (all)</p>	<p>2 / 6 (33.33%) 2</p>		
<p>Skin and subcutaneous tissue disorders</p> <p>DRY SKIN subjects affected / exposed occurrences (all)</p> <p>HYPERHIDROSIS subjects affected / exposed occurrences (all)</p> <p>RASH PRURITIC subjects affected / exposed occurrences (all)</p> <p>SEBORRHOEIC DERMATITIS subjects affected / exposed occurrences (all)</p> <p>SKIN FISSURES</p>	<p>1 / 6 (16.67%) 1</p> <p>1 / 6 (16.67%) 1</p> <p>2 / 6 (33.33%) 2</p> <p>1 / 6 (16.67%) 1</p>		

subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1		
Psychiatric disorders SLEEP DISORDER subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1		
Musculoskeletal and connective tissue disorders ARTHRALGIA subjects affected / exposed occurrences (all) BONE PAIN subjects affected / exposed occurrences (all) MYALGIA subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1 1 / 6 (16.67%) 1 1 / 6 (16.67%) 1		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
19 April 2012	The reason for partial clinical hold was the occurrence of pancreatitis cases reported in other DEB025 trials. Seven cases of pancreatitis (including one fatal case) had been reported for patients treated with DEB025/pegIFN/RBV among approximately 1800 patients on DEB025 treatment in the phase II/III development program. Due to premature termination of the study and very limited dataset (only six patients enrolled), the planned data analyses were not performed.	-

Notes:

Limitations and caveats

None reported